Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Radiotherapy Followed by Immunotherapy in Esophageal Squamous Cell Carcinoma
NCT05937438Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab and camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: 1-year Disease-Free Survival. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumabcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05937438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937438.